Poster: HL-370 Fragmentome Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma
Lodovico Terzi di Bergamo(Institute of Oncology Research), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Salvatore Annunziata(Agostino Gemelli University Polyclinic), Stefan Hohaus, Marcello Rodari(Humanitas University), Luigi Maria Larocca(Agostino Gemelli University Polyclinic), Luca Ceriani(St Thomas' Hospital), Maria Cristina Pirosa(Institute of Oncology Research), Joyce Marques de Almeida(Institute of Oncology Research), Eugenio Borsatti(Centro di Riferimento Oncologico), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Pietro Bulian(Centro di Riferimento Oncologico), Michał Kurlapski(University Clinical Centre), Adalgisa Condouci(Institute of Oncology Research), Alessandra Stasia(Institute of Oncology Research), Bernhard Gerber, Andrea Rinaldi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Martina Di Trani(Humanitas University), Deborah Piffaretti(Institute of Oncology Research), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Carmelo Carlo‐Stella(Humanitas University), Stéphane Chauvie(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Marco Cuzzocrea(Institute of Oncology Research), Anastasios Stathis(Princess Margaret Cancer Centre), Franco Cavalli(Institute of Social and Preventive Medicine), Katia Pini(Institute of Oncology Research), Jan Zaucha(University of Dundee), Matin Salehi(SIB Swiss Institute of Bioinformatics), Ilaria Zangrilli(Agostino Gemelli University Polyclinic), Grzegorz Romanowicz(Gdańsk Medical University), Gabriela Forestieri(Institute of Oncology Research), Valter Gattei(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), C. Giordano(Federico II University Hospital), Alden A. Moccia(BC Cancer Agency), Gian Mauro Sacchetti(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Simone Bocchetta(Institute of Oncology Research), Armando Santoro(IRCCS Humanitas Research Hospital), Emanuele Zucca(Università della Svizzera italiana), Valeria Spina(Ente Ospedaliero Cantonale), Fabrizio Bergesio(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Georg Stuessi(Institute of Oncology Research), Alessio Bruscaggin(Institute of Oncology Research)
Cited by 0
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Advanced pancreatic carcinoma: current treatment and future challenges
|Nature Reviews Clinical Oncology|2010|791